Anti-BCMA novel therapies for multiple myeloma

被引：19

作者：

Sammartano, Vincenzo ^{[1
]}

Franceschini, Marta ^{[1
]}

Fredducci, Sara ^{[1
]}

Caroni, Federico ^{[1
]}

Ciofini, Sara ^{[1
]}

Pacelli, Paola ^{[1
]}

Bocchia, Monica ^{[1
]}

Gozzetti, Alessandro ^{[1
,2
]}

机构：

[1] Univ Siena, Azienda Ospedaliero Univ Senese, Dept Med Surg & Neurosci, I-53100 Siena, Italy

[2] Univ Siena, Azienda Ospedaliero Univ Senese, Dept Med Surg & Neurosci, Viale Mario Bracci 16, I-53100 Siena, Italy

来源：

CANCER DRUG RESISTANCE | 2023年 / 6卷 / 01期

关键词：

Multiple myeloma; BCMA; belantamab; teclistamab; CART; CELL MATURATION ANTIGEN; NF-KAPPA-B; BELANTAMAB MAFODOTIN; RECEPTOR; SURVIVAL; OUTCOMES; APRIL; EFFICACY; DISEASE; MEMBER;

D O I：

10.20517/cdr.2022.138

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mechanisms, including bispecific T cell engagers drug conjugated to antibody and CAR-T cells, are now available or under development. Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy. This review will discuss the recent development of anti-BCMA targeted treatments in myeloma, with a special focus on currently available agents.

引用

页码：169 / 181

页数：13

共 142 条

[1] Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes [J].

Abdollahpour-Alitappeh, Meghdad ;

Lotfinia, Majid ;

Gharibi, Tohid ;

Mardaneh, Jalal ;

Farhadihosseinabadi, Behrouz ;

Larki, Pegah ;

Faghfourian, Babak ;

Sepehr, Koushan Sineh ;

Abbaszadeh-Goudarzi, Kazem ;

Abbaszadeh-Goudarzi, Ghasem ;

Johari, Behrooz ;

Zali, Mohammad Reza ;

Bagheri, Nader .

JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (05) :5628-5642

[2] T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma [J].

Ali, Syed Abbas ;

Shi, Victoria ;

Maric, Irina ;

Wang, Michael ;

Stroncek, David F. ;

Rose, Jeremy J. ;

Brudno, Jennifer N. ;

Stetler-Stevenson, Maryalice ;

Feldman, Steven A. ;

Hansen, Brenna G. ;

Fellowes, Vicki S. ;

Hakim, Frances T. ;

Gress, Ronald E. ;

Kochenderfer, James N. .

BLOOD, 2016, 128 (13) :1688-1700

[3] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma [J].

Anderson, Larry D., Jr. .

FUTURE ONCOLOGY, 2021, 18 (03) :277-289

[4] Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies [J].

Atilla, Pinar Ataca ;

Atilla, Erden .

TRANSLATIONAL ONCOLOGY, 2022, 22

[5] BAFF selectively enhances the survival of plasmablasts generated from human memory B cells [J].

Avery, DT ;

Kalled, SL ;

Ellyard, JI ;

Ambrose, C ;

Bixler, SA ;

Thien, M ;

Brink, R ;

Mackay, F ;

Hodgkin, PD ;

Tangye, SG .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (02) :286-297

[6] Current Treatment for Multiple Myeloma [J].

Avigan, David ;

Rosenblatt, Jacalyn .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10) :961-962

[7] Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation [J].

Bera, Tapan K. .

BIOMOLECULES, 2020, 10 (10) :1-14

[8] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study [J].

Berdeja, Jesus G. ;

Madduri, Deepu ;

Usmani, Saad Z. ;

Jakubowiak, Andrzej ;

Agha, Mounzer ;

Cohen, Adam D. ;

Stewart, A. Keith ;

Hari, Parameswaran ;

Htut, Myo ;

Lesokhin, Alexander ;

Deol, Abhinav ;

Munshi, Nikhil C. ;

O'Donnell, Elizabeth ;

Avigan, David ;

Singh, Indrajeet ;

Zudaire, Enrique ;

Yeh, Tzu-Min ;

Allred, Alicia J. ;

Olyslager, Yunsi ;

Banerjee, Arnob ;

Jackson, Carolyn C. ;

Goldberg, Jenna D. ;

Schecter, Jordan M. ;

Deraedt, William ;

Zhuang, Sen Hong ;

Infante, Jeffrey ;

Geng, Dong ;

Wu, Xiaoling ;

Carrasco-Alfonso, Marlene J. ;

Akram, Muhammad ;

Hossain, Farah ;

Rizvi, Syed ;

Fan, Frank ;

Lin, Yi ;

Martin, Thomas ;

Jagannath, Sundar .

LANCET, 2021, 398 (10297) :314-324

[9] Targeted Therapy With Immunoconjugates for Multiple Myeloma [J].

Bruins, Wassilis S. C. ;

Zweegman, Sonja ;

Mutis, Tuna ;

van de Donk, Niels W. C. J. .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[10]

Bu De-Xiu, 2018, Oncotarget, V9, P25764, DOI [10.18632/oncotarget.25359, 10.18632/oncotarget.25359]

← 1 2 3 4 5 6 7 8 9 10 →